Pharmacia Italia SpA v Mayne Pharma Pty Ltd

Link copied
Case Copied 51 min read

FEDERAL COURT OF AUSTRALIA

Pharmacia Italia SpA v Mayne Pharma Pty Ltd [2006] FCA 305

PATENTS – infringement of pharmaceutical patent – existing injunction restrains respondents until conclusion of initial term of patent – extension of term of pharmaceutical patent granted prior to infringement proceedings – whether injunction restraining respondents should also apply to period of extension – basis upon which patent capable of extension – whether claim in respect of pharmaceutical substance per se – whether references in patent specifications to elements of “process” or “method” prevent claim from being a claim in respect of a pharmaceutical substance per se – rectification of Register – whether s 192 of Patents Act 1990 (Cth) allows only for the correction of clerical and like errors

ADMINISTRATIVE LAW – application for judicial review – decision by Commissioner of Patents to accept an application, and to fail to refuse to accept an application, for extension of term of patent – decision by Commissioner of Patents to grant an extension of term of patent – whether compound consisting of both therapeutic substance and inert substances is a “pharmaceutical substance” – whether patent for a pharmaceutical substance per se – effect of delay in bringing application for review

WORDS AND PHRASES – “pharmaceutical substance per se”, “pharmaceutical substance”

Administrative Decisions (Judicial Review) Act 1977 (Cth) ss 5 and 11
Judiciary Act 1903 (Cth) s 39B
Patents Act 1990 (Cth) ss 70, 78, 192
Patents Regulations 1991 (Cth) r 5

Boehringer Ingelheim International GmbH v Commissioner of Patents (2001) 112 FCR 595 applied
Boehringer Ingelheim International v Commissioner of Patents (2001) AIPC ¶91-670 followed
Lockwood Security Products Pty Ltd v Doric Products Pty Limited (2004) 217 CLR 274 cited
Pharmacia Italia SpA v Mayne Pharma Pty Ltd (2005) 222 ALR 552 discussed
Prejay Holdings Ltd v Commissioner of Patents (2003) 57 IPR 424 referred to
Rehm Pty Ltd v Websters Security Systems (International) Pty Ltd (1988) 81 ALR 79 cited

PHARMACIA ITALIA SpA and PFIZER (PERTH) PTY LIMITED (FORMERLY PHARMACIA (PERTH) PTY LIMITED) v MAYNE PHARMA PTY LTD, F H FAULDING & CO LTD and FAULDING HEALTHCARE PTY LTD

VID 439 OF 2003

INTERPHARMA PTY LTD v THE COMMISSIONER OF PATENTS and PHARMACIA ITALIA SpA

VID 1274 OF 2005

WEINBERG J
29 MARCH 2006
MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 439 OF 2003

BETWEEN:

PHARMACIA ITALIA SpA
FIRST APPLICANT

PFIZER (PERTH) PTY LIMITED (FORMERLY PHARMACIA (PERTH) PTY LIMITED)
SECOND APPLICANT

AND:

MAYNE PHARMA PTY LTD
FIRST RESPONDENT

F H FAULDING & CO LTD
SECOND RESPONDENT

FAULDING HEALTHCARE PTY LTD
THIRD RESPONDENT

JUDGE:

WEINBERG J

DATE OF ORDER:

29 MARCH 2006

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

1.The parties file proposed minutes of orders in accordance with these reasons for judgment, and any other orders or directions appropriate for the future disposition of the matter, on or before 19 April 2006.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

IN THE…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmacia Italia SpA v Mayne Pharma Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] FCA 305
Decision Date

CaseChat Overview and Summary

The case before the court was Pharmacia Italia SpA v Mayne Pharma Pty Ltd, a dispute involving patent infringement and the validity of a patent term extension. Pharmacia Italia SpA, an Italian company, held a patent for a specific injectable ready-to-use solution containing an antitumor anthracycline glycoside. The patent was licensed to Pfizer (Perth) Pty Limited, which had an exclusive license in Australia for the product known as "epirubicin hydrochloride." The dispute arose when Mayne Pharma Pty Ltd, a competitor, was alleged to have infringed the patent by manufacturing and selling a similar product. The primary legal issue was whether Mayne Pharma's product was made from a lyophilizate, as stated in claim 1 of the patent. A secondary issue involved whether the use of sodium hydroxide, along with hydrochloric acid, to adjust the pH of the solution constituted an avoidance of patent infringement.

The court's reasoning focused on the interpretation of the patent claims, particularly the phrase "not been reconstituted from a lyophilizate" in claim 1. The court considered the specific language and technical details of the patent to determine the scope of protection granted. Additionally, the court examined whether the use of sodium hydroxide, in addition to hydrochloric acid, to adjust the pH of the solution, fell outside the scope of the patent's claims. The court's decision ultimately hinged on the precise interpretation of the patent claims and whether Mayne Pharma's actions fell within or outside these claims.

The court dismissed the application for review brought by Interpharma, a related entity to Mayne Pharma. The dismissal was based on the finding that Interpharma had not acted within a reasonable time to challenge the extension of the patent term. The court found that Interpharma's delay in filing the application for review was unreasonable, particularly given their awareness of the potential infringement and the patent extension decision. Consequently, the court ruled that the application for review was not made within a reasonable time, leading to its dismissal. The court also noted that the substantive merits of Interpharma's application were weak, and the delay further undermined the case for granting relief.

Orders

Orders of the court

1. The parties file proposed minutes of orders in accordance with these reasons for judgment, and any other orders or directions appropriate for the future disposition of the matter, on or before 19 April 2006.

1. The application be dismissed.

2. The applicant pay the second respondent’s costs

Background

Background to the litigation

The answer to this question will determine whether Mayne’s plans regarding its own product, a competitor to that of Pharmacia, can go forward. It will also affect Interpharma’s planning in relation to the products that it intends to market.FACTUAL BACKGROUND Pharmacia, a company incorporated in Italy, is the registered proprietor of the Patent. The Patent is titled “Injectable ready-to-use solutions containing an antitumor anthracycline glycoside”. In simple terms, the ready-to-use solution of the invention can be described as a mixture of: ·a solute (the anthracycline glycoside);·a solvent; and ·an acid. The second applicant in the Pharmacia Proceeding, Pfizer (Perth) Pty Limited (formerly Pharmacia (Perth) Pty Limited) (“Pfizer”), is a company incorporated in Australia. Since 1 June 2003, it has had an exclusive licence in this country in respect of the invention described in the Patent in relation to a product known as “epirubicin hydrochloride”. The first respondent in the Pharmacia Proceeding, Mayne Pharma Pty Ltd is a manufacturer, distributor and exporter of pharmaceutical products. The second and third respondents, F H Faulding & Co Ltd and Faulding Healthcare Pty Ltd are related entities and form part of the Mayne Pharma group of companies. The Patent commenced on 19 June 1986, with a priority date of 2 August 1985. The original term of the Patent was 20 years, ending on 19 June 2006. On 14 March 2001, Pharmacia applied to the Commissioner to extend the Patent, and on 24 October 2001, the Commissioner accepted the extension application. The effect of that acceptance was to trigger the operation of various procedures under the Patents Act enabling the application to be considered. On 6 April 2002, the Commissioner granted Pharmacia a five year extension of the term of the Patent to 19 June 2011. There was no opposition at that stage to the grant of the extension. As previously indicated, Pharmacia and Pfizer subsequently brought the Pharmacia Infringement Proceeding against Mayne, under ss 117 and 120 of the Patents Act, alleging that Mayne had infringed certain claims of the Patent by “manufacturing, selling, using and keeping a ready-to-use antitumor anthracycline glycoside solution as claimed in the Patent”. The only question resolved in that proceeding was whether Mayne had infringed certain claims of the Patent by making and selling epirubicin hydrochloride in injectable ready-to-use solutions. Liability was dealt with separately from any question of damages, or account of profits, which issues remain unresolved. According to Crennan J, at [4] of her reasons for judgment, the primary issue in relation to infringement was whether Mayne’s product had “not been reconstituted from a lyophilizate”, as that phrase appeared in claim 1 of the Patent. A secondary issue identified by her Honour was whether Mayne avoided infringement on the specific occasions on which they used sodium hydroxide, in addition to hydrochloric acid, to adjust the pH of the solution, given that claim 1 of the Patent refers to the pH being adjusted “solely with a physiologically acceptable acid”.

Decision

Reasons for decision

WEINBERG J
Ms Strong also made a number of submissions regarding the timing of Interpharma’s application for review. She noted that s 11(4) of the ADJR Act provides this Court with the discretion to refuse to entertain an application for an order of review if “the court is of the opinion that the application was not made within a reasonable time after the decision was made” (emphasis added).She also noted that when forming its opinion, s 11(5) of that Act provides that the Court “shall have regard to the time when the applicant became aware of the making of the decision; and…may have regard to such other matters as it considers relevant.” Ms Strong then sought to explain, and to justify, Interpharma’s delay. On this point, Ms Strong submitted that there was nothing in the evidence led on behalf of Pharmacia to suggest that it would, in any way, be prejudiced if time were extended to allow the application for review to proceed. She described that evidence as “broadbrush” and speculative. She further submitted that Interpharma had acted reasonably in assuming that the processes by which EBEWE Pharma proposed to manufacture doxorubicin EBEWE and epirubicin EBEWE for the Australian market did not come within the claims specified in the Patent. Ms Strong argued that it was not until Interpharma was in a position to market doxorubicin EBEWE, in about August 2005, after the judgment of Crennan J in the Pharmacia Infringement Proceeding had been delivered, that it was reasonable to expect Interpharma to challenge the extension of the Patent. Interpharma had filed its application for review of the Commissioner’s decisions on 11 October 2005, not long after her Honour’s judgment had become available. According to Ms Strong, “[f]rom August 2005, Interpharma moved with great expedition”. It should be remembered that Interpharma also relied upon s 39B of the Judiciary Act in challenging the validity of the Commissioner’s decision to grant the extension of the Patent. Ms Strong noted that there was no specific time limit, under the Federal Court Rules, for the grant of certiorari, which was the principal remedy sought. It was only necessary, as a matter of discretion, to persuade the Court that relief should not be withheld by reason of excessive delay. She submitted that in context, the delay was adequately explained. Finally, Ms Strong sought to invoke s 192 of the Patents Act, as a separate basis upon which relief should be granted. That section allows for rectification of the Register. She submitted that the need to ensure that the Register was properly maintained justified the relief sought, no matter how long, or how unjustified, the delay might be.PHARMACIA’S SUBMISSIONS Mr Caine accepted that at least from 22 May 2003 (the date on which Interpharma signed an exclusive Supply and Distribution Agreement with EBEWE Pharma), Interpharma was a “person aggrieved” within the meaning of section 5(1) of the ADJR Act. For the reasons outlined in his submissions in the Pharmacia Proceeding, Mr Caine contended that the Commissioner had been justified in extending the term of the Patent. He therefore submitted that the substantive merits of Interpharma’s application were conspicuously weak, a matter that was relevant when considering whether to grant an extension of time for the application for review.

Ratio Decidendi

Legal Principle Established

Established by: WEINBERG J

Under the Administrative Decisions (Judicial Review) Act 1977, the Court has the discretion to refuse to entertain an application for an order of review if it is not made within a reasonable time after the decision was made. The Court must consider the time when the applicant became aware of the decision and any other relevant matters. The Court found that Interpharma's delay in filing the application was not adequately explained and amounted to an unreasonable delay. Interpharma had been aware of the Commissioner's decision to extend the patent term since 6 April 2002, but did not file its application for review until 11 October 2005. The Court held that Interpharma's assumption that the processes by which EBEWE Pharma proposed to manufacture doxorubicin EBEWE and epirubicin EBEWE for the Australian market did not come within the claims specified in the Patent was not a sufficient justification for the delay. Furthermore, the Court held that s 192 of the Patents Act, which allows for rectification of the Register, did not provide a basis for granting relief in this case, as the need to ensure that the Register was properly maintained did not justify the delay. The Court also held that the Commissioner's decision to extend the patent term was justified and that Interpharma did not have standing to challenge this decision. The Court found that the Commissioner had acted within his statutory powers and that there was no evidence to suggest that the decision was flawed or unjust. The Court dismissed the application for review and ordered that the applicant pay the second respondent's costs.